CAR-T/Transgene/Cytokine/Biomarker Quantification and Statistical Analysis

Chimeric antigen receptor (CAR) T cell therapy is highly effective in treating hematologic malignancies, and major efforts are being made to achieve similar efficacy in solid tumors. Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma, respectively. From then, increasing number of researchers have been dedicated to CAR-T cell therapy research around the world. In CAR-T cell therapies the collection of patient's T cells is followed by a genetic modification of these immune cells to obtain the expression of chimeric antigen receptors specific for the tumor cell of interest. After the characterization and expansion ex vivo, they are re-infused to the patient to fight against the patient's tumor cells. So, determining the CAR distribution is central for the safety assessment of proposed early-phase clinical trials. The RNA ISH assay enables single molecule detection of CAR, transgene mRNA, and/or specific biomarkers in the tissue at the single-cell level, thus allowing for a high spatial resolution at both the cellular and subcellular levels. RNA ISH assay from Creative Bioarray allows visualization and quantification of CAR presence, transgene, and biomarker expression in treated tissue samples.

We are capable of offering CAR-T/Transgene/Cytokine/Biomarker Quantification and Statistical Analysis service in the most high-quality and cost-effective way. Following the current FDA guidelines, our experienced scientists will design the most appropriate experiment plan to meet every client's specific requirement.

Benefits of CAR-T/Transgene/Cytokine/Biomarker Quantification and Statistical Analysis (RNA ISH method)

(1) Activated CAR-T cell detection and quantification in intact fixed tissue
(2) Quantifiable assays to measure percentage of cells positive for CAR, transgene and biomarker expression
(3) Quantify CAR+ cell number and track persistence over time

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your CAR-T/Transgene/Cytokine/Biomarker Quantification and Statistical Analysis partner.

References

1. Wang F, et al. RNAscope®: A novel in situ RNA analysis platform for formalin-fixed, paraffinembedded tissues. J Mol Diagn. 2012; 14(1):22–9.
2. O'Rourke DM, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017; 9(399): pii: eaaa0984.
3. Wing A, et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018; 6(5):605–16.